Is Palopegteriparatide legal in the US?
Yes, FDA approved for low parathyroid hormone in adults.
AStrong human evidenceFDA approvedas of 2026-10-26
Approved in 2024 as Yorvipath for the treatment of hypoparathyroidism in adults, given as a once-daily subcutaneous injection. The label carries a warning about a potential osteosarcoma risk based on rat studies of parathyroid hormone analogs. 2
Read the full Palopegteriparatide page
More on Palopegteriparatide
Citations
- Khan 2023, J Bone Miner Res: efficacy and safety of palopegteriparatide (TransCon PTH) in adults with hypoparathyroidism, PaTHway phase 3 trial pubmed.ncbi.nlm.nih.gov
- Ascendis Pharma: Yorvipath (palopegteriparatide) prescribing information ascendispharma.us
- Khan 2026, J Clin Endocrinol Metab: palopegteriparatide in adults with hypoparathyroidism, 3.5-year results from the phase 3 PaTHway trial pubmed.ncbi.nlm.nih.gov
Reference information only, not medical advice. Drawn from the Palopegteriparatide article, fact-checked against the cited sources. No dosing anywhere on this site.